Adagio Medical Publishes Results of Ultrawlow Temperature Cardiac Ablation Study
Adagio Medical announced the publication of results from the U.S. Early Feasibility study evaluating ultralow temperature cardiac ablation for the treatment of scar-related ventricular tachycardia. Results demonstrated a favorable safety profile, with no device, or procedure-related major adverse events measured at both seven and 30 days, and strong acute and chronic performance. "The advantage of Adagio's ULTC technology in ablation of ventricular tachycardia compared to the conventional technologies is its ability to produce deep, titratable lesions required to treat the significant patient population with deep intramural substrate that cause their VT," said Peter Weiss, associate professor of Medicine at the University of Arizona College of Medicine, Phoenix, and corresponding author of the study. "The results of this EFS were similar to the already highly encouraging results of the CRYOCURE-VT European study, albeit in a more challenging, heavily non-ischemic patient population and with very aggressive de-escalation of antiarrhythmic medication."
